Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 8/20 | 0.65 |
| ▸ | EHMT1 | Q9H9B1 | 8/20 | 0.65 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.63 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.63 |
| ▸ | KIT | P10721 | 2/20 | 0.62 |
| ▸ | RET | P07949 | 3/20 | 0.61 |
| ▸ | KIF5B | P33176 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 3/20 | 0.60 |
| ▸ | SPIN1 | Q9Y657 | 2/20 | 0.58 |
| ▸ | EGFR | P00533 | 4/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.57 |
| ▸ | FLT1 | P17948 | 2/20 | 0.57 |
| ▸ | FLT4 | P35916 | 2/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.56 |
| ▸ | PLK4 | O00444 | 1/20 | 0.56 |
| ▸ | GAK | O14976 | 1/20 | 0.56 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.56 |
| ▸ | ERN1 | O75460 | 1/20 | 0.56 |
| ▸ | STK10 | O94804 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2475406 | 0.99 | EHMT2 (0.64) | EHMT2EHMT1TLR9TLR7KIT | |
| SCHEMBL5495221 | 0.90 | SRC (0.66) | KITRETKIF5BKDREGFR | |
| SCHEMBL25281864 | 0.90 | SRC (0.66) | KITRETKIF5BKDREGFR | |
| SCHEMBL4426202 | 0.87 | EHMT2 (0.70) | EHMT2EHMT1TLR9TLR7KIT | |
| SCHEMBL2921945 | 0.87 | ENPP1 (0.65) | EHMT2EHMT1TLR9TLR7KIT | |
| SCHEMBL3955512 | 0.87 | ENPP1 (0.65) | EHMT2EHMT1TLR9TLR7KIT | |
| SCHEMBL13355147 | 0.87 | EHMT2 (0.64) | EHMT2EHMT1TLR9TLR7KIT | |
| SCHEMBL4431962 | 0.86 | EHMT2 (0.69) | EHMT2EHMT1TLR9TLR7KIT | |
| SCHEMBL4430442 | 0.86 | EHMT2 (0.69) | EHMT2EHMT1TLR9TLR7KIT | |
| SCHEMBL2924110 | 0.86 | ENPP1 (0.64) | EHMT2EHMT1TLR9TLR7KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| EP-1553097-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| EP-1154774-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| EP-0912557-B1 | OXINDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-07-09 | — | — | EP | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| US-6265411-B1 | ANGIOGENESIS INHIBITOR | ZENECA LIMITED (GB) | 2001-07-24 | — | — | US | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| EP-0912557-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997042187-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | EHMT2 4727/4885EHMT1 4270/4885TLR9 1534/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | EHMT2 3239/4885EHMT1 2438/4885TLR9 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.